You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Aspen Neuroscience, Inc. completed its IPO on November 2, 2026, selling 9,375,000 common shares at $15.00 per share and generating approximately $140.6 million in gross proceeds before underwriting discounts, commissions and offering expenses. Its amended certificate and bylaws became effective.
Aspen Neuroscience, Inc. proposes an initial public offering of 9,375,000 common shares at $15.00 to $17.00 per share and plans to list under “ASPE” on Nasdaq Global Select Market. Its sasineprocel ASPIRO trial had dosed 15 patients by August 18, 2026.
Aspen Neuroscience, Inc. proposes an initial public offering of common stock and plans to list on Nasdaq under “ASPE”; in the Phase 1/2a ASPIRO trial, 15 patients had been dosed as of August 18, 2026, with sasineprocel generally well-tolerated.
Aspen Neuroscience, Inc. is pursuing an initial public offering of common stock and plans to list it on Nasdaq Global Select Market under “ASPE.” Its lead candidate, sasineprocel, is being evaluated for Parkinson’s disease, with 15 patients dosed.
